Chen Wei R, Liu Hong, Ritchey Jerry W, Bartels Kenneth E, Lucroy Michael D, Nordquist Robert E
Department of Physics and Engineering, University of Central Oklahoma, Edmond, Oklahoma 73034, USA.
Cancer Res. 2002 Aug 1;62(15):4295-9.
Induction of a long-term tumor-specific immunity is the ultimate cure of metastatic cancers. Laser immunotherapy is a novel approach that aims at the tumor-directed stimulation of the immune system of the host. It involves an intratumor administration of a laser-absorbing dye and an immunoadjuvant, followed by noninvasive laser irradiation. Previous studies using glycated chitosan (GC) as immunoadjuvant and indocyanine green (ICG) as laser-absorbing dye have shown positive effects of the treatment on metastatic breast tumors in rats. In vivo experiments showed promising results such as: (a) eradication of treated primary tumors; (b) regression of untreated metastases; (c) induced antitumor immune response; and (d) long-term resistance to tumor rechallenge. In this study, rats bearing metastatic breast tumors and metastatic prostate tumors were treated with various combinations of the three components of laser immunotherapy. The rat survival rates and profiles of primary and metastatic tumors, after treatment by individual components and various combinations of the components, were analyzed. In the treatment of breast tumors, all of the experimental groups without immunoadjuvant showed little or no positive effect. The use of GC, either by itself or in combination with other components, had a noticeable impact on the survival rate of tumor-bearing rats. However, it was the combination of all of the three components that resulted in the highest cure rate. Three different concentrations of GC, 0.5, 1, and 2%, were also used to treat the metastatic breast tumors. The results showed that 1% GC was most effective in laser immunotherapy. In the treatment of metastatic prostate tumors, both the laser-ICG and laser-ICG-GC treatments significantly reduced the growth of primary tumors and lung metastases. Long-term survival of the rats bearing the prostate tumors was also observed after the laser immunotherapy treatment in our preliminary studies. These results revealed the important function of the immunoadjuvant in laser immunotherapy.
诱导长期的肿瘤特异性免疫是转移性癌症的最终治愈方法。激光免疫疗法是一种旨在针对肿瘤定向刺激宿主免疫系统的新方法。它包括在肿瘤内注射一种激光吸收染料和一种免疫佐剂,随后进行非侵入性激光照射。先前使用糖化壳聚糖(GC)作为免疫佐剂和吲哚菁绿(ICG)作为激光吸收染料的研究表明,该治疗方法对大鼠转移性乳腺肿瘤有积极作用。体内实验显示出有前景的结果,如:(a)根除治疗的原发性肿瘤;(b)未治疗的转移灶消退;(c)诱导抗肿瘤免疫反应;以及(d)对肿瘤再攻击的长期抗性。在本研究中,对患有转移性乳腺肿瘤和转移性前列腺肿瘤的大鼠用激光免疫疗法的三种成分的各种组合进行治疗。分析了单独成分和成分的各种组合治疗后大鼠的存活率以及原发性和转移性肿瘤的情况。在乳腺肿瘤的治疗中,所有没有免疫佐剂的实验组几乎没有或没有积极作用。单独使用GC或与其他成分联合使用对荷瘤大鼠的存活率有显著影响。然而,三种成分全部联合使用导致治愈率最高。还使用三种不同浓度的GC,即0.5%、1%和2%来治疗转移性乳腺肿瘤。结果表明,1%的GC在激光免疫疗法中最有效。在转移性前列腺肿瘤的治疗中,激光-ICG和激光-ICG-GC治疗均显著降低了原发性肿瘤和肺转移灶 的生长。在我们的初步研究中,激光免疫疗法治疗后也观察到了患有前列腺肿瘤大鼠的长期存活。这些结果揭示了免疫佐剂在激光免疫疗法中的重要作用。